Sartorius Stedim Biotech strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix

Author's Avatar
Jul 02, 2021

- Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

- CellGenix site in Freiburg to be expanded into a center of excellence for the development and production of cell culture components

PR Newswire